Browse PTGER3

Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition of sodium and water reabsorption in kidney tubulus and contraction in uterine smooth muscle. The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G-I proteins, and to an elevation of intracellular calcium. The various isoforms have identical ligand binding properties but can interact with different second messenger systems (By similarity).

> Gene Ontology
 
Biological Process GO:0001659 temperature homeostasis
GO:0001660 fever generation
GO:0001696 gastric acid secretion
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0003012 muscle system process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0006953 acute-phase response
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007586 digestion
GO:0014821 phasic smooth muscle contraction
GO:0014827 intestine smooth muscle contraction
GO:0014831 gastro-intestinal system smooth muscle contraction
GO:0022600 digestive system process
GO:0031349 positive regulation of defense response
GO:0031620 regulation of fever generation
GO:0031622 positive regulation of fever generation
GO:0031649 heat generation
GO:0031650 regulation of heat generation
GO:0031652 positive regulation of heat generation
GO:0032103 positive regulation of response to external stimulus
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0044057 regulation of system process
GO:0044058 regulation of digestive system process
GO:0046717 acid secretion
GO:0048871 multicellular organismal homeostasis
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060453 regulation of gastric acid secretion
GO:0060455 negative regulation of gastric acid secretion
GO:0060457 negative regulation of digestive system process
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
Molecular Function GO:0004953 icosanoid receptor activity
GO:0004954 prostanoid receptor activity
GO:0004955 prostaglandin receptor activity
GO:0004957 prostaglandin E receptor activity
Cellular Component GO:0005635 nuclear envelope
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-391903: Eicosanoid ligand-binding receptors
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-391908: Prostanoid ligand receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTGER3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTGER3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23390011Colon CarcinomaPromote immunityPGE2 signals through four different receptors (EP1-EP4) and targeting individual receptor(s) may avoid these side effects, while retaining significant anticancer benefits. This antitumor effect was associated with reduced Fas ligand expression and attenuated tumor-induced immune suppression. In particular, tumor infiltration by CD4(+) CD25(+) Foxp3(+) regulatory T cells was decreased, whereas the cytotoxic activity of isolated splenocytes against CT26 cells was increased.
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTGER3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTGER3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4370.375
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5310.531
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3420.576
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4250.414
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5690.764
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2540.905
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3910.552
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9310.367
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1150.914
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.280.394
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2410.54
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5390.0549
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTGER3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTGER3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTGER3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTGER3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTGER3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTGER3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTGER3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTGER3
Nameprostaglandin E receptor 3 (subtype EP3)
Aliases EP3; EP3-I; EP3-II; EP3-III; EP3-IV; EP3-VI; EP3e; PGE2-R; PGE receptor, EP3 subtype; PGE2 receptor EP3 subt ......
Chromosomal Location1p31.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTGER3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTGER3.
ID Name Drug Type Targets #Targets
DB00905BimatoprostSmall MoleculeAKR1C3, PTGER1, PTGER3, PTGFR4
DB00917DinoprostoneSmall MoleculePTGDR2, PTGER1, PTGER2, PTGER3, PTGER45
DB00929MisoprostolSmall MoleculePTGER2, PTGER3, PTGER43
DB08964GemeprostSmall MoleculePTGER2, PTGER32
DB09211LimaprostSmall MoleculePTGER1, PTGER2, PTGER3, PTGER44